Saffron Extract (Affron 28 mg) — Supplements
Standardized saffron stigma extract with meta-analysis-level evidence for anxiety, depression, and sleep disturbance — comparable to SSRIs without dependence.
Overview
Saffron (Crocus sativus L.) is one of the most extensively studied botanical supplements for mood and sleep disorders. A 2024 systematic review analyzing 46 RCTs confirmed superiority over placebo for anxiety (effect size −3.75), depression (effect size −4.26), and sleep disorders (effect size −1.91). Multiple head-to-head trials demonstrate non-inferiority to SSRIs (fluoxetine, citalopram, sertraline) and imipramine for mild-to-moderate depression and anxiety, with a significantly more favorable side-effect profile. The most clinically studied branded extract is Affron (Pharmactive Biotech Products), standardized to ≥3.5% lepticrosalides per 28 mg capsule. A 2025 RCT in 202 adults using 28 mg Affron for 12 weeks showed 72.3% achieved clinically significant improvement vs 54.3% on placebo (p=0.010). Saffron's anxiolytic and antidepressant mechanism involves inhibition of serotonin reuptake (SERT), monoamine oxidase (MAO) inhibition, NMDA receptor modulation, and anti-inflammatory activity via crocin and safranal metabolites.
Indications
- Mild to moderate depression
- Generalized anxiety and subthreshold anxiety
- Sleep disturbance and insomnia
- Premenstrual syndrome (PMS) and mood dysregulation
- Cognitive support in aging populations
Mechanism of Action
Safranal and crocin inhibit the serotonin reuptake transporter (SERT), increasing synaptic serotonin availability in limbic circuits — a mechanism shared with SSRIs but at lower potency, without receptor downregulation
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Saffron extract (Affron, standardized ≥3.5% lepticrosalides) | 28 mg | Once daily | Branded extract used in key RCTs; onset 2-4 weeks for mood, 1-2 weeks for sleep |
| Saffron extract (Safr'Inside) | 15-30 mg | Once daily | Alternative branded extract with growing evidence base; used in 2025 German sleep RCT |
Evidence Grade
GRADE C
Safety & Contraindications
- Excellent tolerability — most common AEs are mild GI discomfort (headache, nausea) comparable to placebo in trials
- Not for use in pregnancy at high doses — saffron has uterotonic properties at culinary doses >5g; supplement doses (28-30 mg/day) appear safe but insufficient pregnancy data
- Theoretical MAO inhibition — use caution when combining with other serotonergic agents (SSRIs, SNRIs, triptans) due to theoretical serotonin syndrome risk, though no clinical cases reported at supplement doses
- May slightly lower blood pressure — monitor in hypotension or antihypertensive drug users
- Adulteration risk: pharmaceutical-grade branded extracts (Affron, Saffr'Inside) strongly preferred over commodity saffron products